The Board of Director of Endo, a specialty pharma and generics company, reports that the company's President and CEO, Blaise Coleman, departed the company, effective August 29, 2024, and that the company has named Scott Hirsch, currently a member of Endo's Board, as the company's Interim CEO. The company has initiated a search for a new CEO and Hirsch will continue to serve as Interim CEO during the transition period while the search is ongoing.